Compare Biogen Inc (BIIB) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Banco Santander SA — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Banco Santander SA trades at $14.84 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 7× Biogen Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SAN | |
|---|---|---|
Market Cap | $30.13B | $211.63B |
Sector | Health | Financials |
52-Week High | $216.63 | $14.71 |
52-Week Low | $128.93 | $9.37 |
Enterprise Value | $37.20B | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Banco Santander (SAN) trades at $14.83, up 0.92% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, beating estimates in Q1 but missing in Q2, while net income grew to $14.10 billion in 2025. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, enhancing its U.S. footprint.
Outlook is supported by analyst consensus (64% buy ratings) and record profitability, but risks include volatile earnings, high debt levels, and integration challenges from acquisitions. The stock's valuation appears reasonable with a P/E of 14.4, offering potential for growth if execution remains strong amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
